10 nov: Transaktioner i forbindelse med Novozymes’ aktietilbagekøbsprogra..
10 nov: Prøveauktion
10-11-2017 11:50:23

USPTO approves BioPorto’s NGAL Trauma patent for issuance

Relateret indhold
Relateret debat
13 jul - 
Njaaah, okay så 😊
13 jul - 
Det er jo faktisk også det jeg skriver
13 jul - 
hofpeung - jeg forstår din tilgang, men tingene kan ogs..

United States Patent and Trademark Office (USPTO) has announced, that BioPorto's NGAL Trauma patent, specifically relating to diagnosing and treating radiation injury, has been approved for issuance.

BioPortos’ issued patents in the US now comprises BioPorto’s NGAL Ratio patent and issued NGAL patent in-licensed from The Trustees of Columbia University. In addition to the issued NGAL patents BioPorto has a number pending NGAL patent applications in the US. Please see BioPorto’s Annual Report for a description of all BioPorto’s issued patents and applications.

Peter Mørch Eriksen, CEO of BioPorto, comments: "We are very pleased that the NGAL Trauma patent is now approved for issuance in the US after a long period of waiting for issuance of new diagnostic patens in the US. Along with the other patents in our IP portfolio it ensures our coverage and we maintain our position as a major player in the NGAL market.”

For further information, please contact:

 

Gry Husby Larsen, General Counsel

Peter M. Eriksen, CEO

Telephone +45 4529 0000, e-mail investor@bioporto.com

 

About BioPorto

BioPorto Diagnostics A/S is an in-vitro diagnostics company that provides healthcare professionals in clinical and research settings a range of diagnostic tests and antibodies. Our pioneering product portfolio includes assays for underserved disease states such as NGAL for acute kidney injury. BioPorto has its headquarters in Copenhagen, Denmark and is listed on the Nasdaq Copenhagen stock exchange.

 

Opret kommentar

Relateret debat

  • 1 uge
  • 1 måned
  • 1 År
12 jul
BIOPOR
Så er der under 20 dage (10 børsdage) tilbage til de skal indsende deres FDA bliver spændende og se ..
1

Fondsbørsmeddelelser

#

EuroInvestor: I fokus
#

#

EuroInvestor: I fokus
#

#

EuroInvestor: I fokus
#

Mest læste nyheder

  • 24 timer
  • 48 timer
  • 1 uge
1
Vestas/UBS: Indleder med købsanbefaling og ser aktien stige 37 pct.
2
Novo/ABM: Recepttal understøtter forventning om opjustering
3
Genmab/Jefferies: Darzalex øger tilliden til ledelsens forventninger
4
Aktier/tendens: Genmab og kolleger får udlandsnyt i let nervøs åbning
5
Aktier/åbning: Vestas fører an i positivt C25-indeks

Relaterede aktiekurser

BioPorto A/S 3,150 0,5% Stigning i aktiekurs

Køb- og salgsanbefalinger

  • Trend
  • Pengemaskinen

Seneste nyheder


Copyright Euroinvestor A/S 2018  Disclaimer  |  Cookie- og privatlivspolitik  |  Persondatapolitik
Aktieinformation leveres af Morningstar.
Data er forsinket 15-20 minutter iht. de enkelte børsers regler om videredistribution.
 
18. juli 2018 02:48:33
(UTC+01:00) Brussels, Copenhagen, Madrid, Paris
Version: LiveBranchBuild_20180712.1 - EUROWEB3 - 2018-07-18 02:48:33 - 2018-07-18 02:48:33 - 1 - Website: OKAY